Objectives: Adapting and testing a novel measure of family planning self-efficacy (FPSE) and examining its association with fertility intention and contraceptive use in India.
Study Design: Data were analyzed from 13,901 non-sterilized, currently married women of reproductive age (15-49 years) in the Bihar Integrated Family Planning Survey (BIFS) 2021. We adapted an FP Self Efficacy measure comprising women's agency to overcome barriers to accessing, discussing and using contraception, regardless of family pressure and social judgment.
While the dominant patterns of migration for livelihood among the poor in India are rural-to-rural and circular, literature on the health implications of child migration has largely focused on rural-to-urban, permanent movement. We compared child growth across three migration typologies rural Bihar: circular migrant families that repeatedly migrate to rural destination sites with accompanying young children, rural households with male migrants, and rural households that do not engage in migration. We integrated network theory based on caste and tribe geography to inform our analytical approach.
View Article and Find Full Text PDFBackground: To reduce burden of pneumonia, India has introduced Pneumococcal Conjugate vaccine (PCV) in routine immunization programme. The state of West Bengal, India introduced PCV in 2021. Uptake of new vaccines depends a lot on knowledge of caregivers on the disease and vaccine This study aimed to assess the knowledge of caregivers regarding pneumococcal diseases and PCV.
View Article and Find Full Text PDFIntroduction: In the Rituximab for Relapse Prevention in Nephrotic Syndrome (RITURNS) trial, we demonstrated superior efficacy of single-course rituximab over maintenance tacrolimus in preventing relapses in children with steroid dependent nephrotic syndrome (SDNS) during a 1-year observation. Here we present the long-term outcomes of all 117 trial completers, who were followed up for another 2 years.
Methods: Relapsing patients in the rituximab arm received a second course of rituximab, either with ( = 44) or without mycophenolate mofetil (MMF) cotreatment ( = 15).